NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorKaiser Permanente
About this trial
A Randomized, Double-blind, placebo-controlled Trial to Evaluate the Efficacy of Oral Nam for the Prevention of Acute Kidney Injury in Patients Undergoing On-Pump Cardiac Surgery
Eligibility criteria
Qualifiers
Informed consent before any study-related activities.
Men or women >18 years of age who are scheduled for non-emergent cardiac surgery procedures requiring CPB and are at increased risk for surgery-related adverse cardiovascular outcomes.
CABG
Aortic, mitral, tricuspid, or pulmonic valve replacement or repair
Disqualifiers
Preexisting AKI within seven days before surgery as defined by KDIGO stage ≥1 (serum creatinine-based)
Kidney transplant status
Off-pump cardiac surgery
ESRD
Trial design
Treatments tested in this trial
- Niacinamide
- Placebo
Treatment groups
304 Participants
are divided into 2 treatment groupsLocations
1Kaiser Permanente San Francisco Medical Center94115, San FranciscoCalifornia, United States
Sponsors and collaborators
Kaiser Permanente
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Beth Israel Deaconess Medical Center
Collaborator
Cedars-Sinai Medical Center
Collaborator
Source ClinicalTrials.gov